Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate
Status:
RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to investigate the uptake characteristics of \[18F\]CETO in adrenal tissue in patients with two different subtypes of primary aldosteronism. The main questions it aims to answer are:
* What are the uptake characteristics of \[18F\]CETO in adrenal tissue in patients with primary aldosteronism?
* What is the concordance between the adrenal vein sampling and the \[18F\]CETO PET/CT scan results?
* What is the effect of adrenal perfusion on \[18F\]CETO uptake in the adrenal glands?
Researchers will compare the results of the adrenal vein sampling to a \[18F\]CETO PET/CT scan to see if the PET/CT can accurately identify the subtypes of primary aldosteronism. Participants will:
* Take dexamethasone three days prior to the scan
* Undergo a \[18F\]CETO PET/CT
* Report burden of pre-treatment and PET/CT scan